Incyte to Market Drug Profiling System from MDS Pharma and Iconix | GenomeWeb

NEW YORK, Dec. 12 — MDS Pharma Services and Iconix Pharmaceuticals announced Wednesday an agreement to develop a new system to evaluate drug efficacy and toxicity. The system, called DrugMatrix, will combine chemical, genomic, and pharmacological information to allow for rapid profiling of drug candidates. Incyte, which entered an agreement with and made an equity investment in Iconix in May 2001, will commercialize the new platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.